LONDON – Six weeks on from the initial alert, “the window of opportunity” to control the COVID-19 epidemic is “narrowing,” according to the latest assessment from WHO Director General Tedros Adhanom Ghebreyesus.
Keeping you up to date on recent developments in oncology, including: Study demonstrates time travel possible for pancreatic cancer; Angle’s Parsotix fares well in new study; New technique boosts utility of organoids; Smart microwaves take on breast cancer.
Keeping you up to date on recent developments in cardiology, including: Using AI to predict heart attacks, stroke; Startup focuses on nano-capsules derived from milk to deliver heart drug; Biotronik sees positive results with ultrathin strut DES.
Keeping you up to date on recent developments in neurology, including: Therapeutic cooling targets site of newborn brain injury; Boys with inattention-hyperactivity face increased risk for traumatic brain injuries; Nanogold improves MS symptoms; Thanks for the memories, myelin.
LONDON – Six weeks on from the initial alert, “the window of opportunity” to control the COVID-19 epidemic is “narrowing,” according to the latest assessment from World Health Organization (WHO) Director General Tedros Adhanom Ghebreyesus.
BioWorld looks at translational medicine, including: Noncoding RNA protects blood vessel walls; PD-1 blockade interferes with opioid analgesia; T-cell population is biomarker for beta cell function; Glutaminase 1 is NASH target; Oligodendrocyte-neural connections not just about myelin; Sharper look yields new potential kinase target in ovarian cancer; Structural insights could enable specific activation of GPCRs; Autophagy activation may prevent metastasis; AI finds structurally unique antibiotics.
Keeping you up to date on recent developments in diagnostics, including: Detailed mapping of breast tumors sheds light on role of genetic variations; Leveraging AI in breast cancer diagnosis; T cell population is biomarker for β-cell function; Oligodendrocyte-neural connections not just about myelin.
Beyond every binary is a more complex reality. And so it is with driver and passenger mutations. The separation of tumor mutations into drivers and passengers underpins much progress in the development of targeted therapies. By looking at passenger mutations more carefully, though, researchers at Yale University have shown that passenger mutations, too, played a role in how tumors progressed.
Keeping you up to date on recent developments in orthopedics, including: In2bones reports U.S. Launch of the Avenger radial head prosthesis; Searching for biomarkers and therapeutic agents against breast cancer; MRI findings predict shoulder stiffness for rotator cuff tears.
Parkinson’s disease (PD) is a neurodegenerative disorder. But not just. And it may not start that way.
There is increasing evidence that a-synuclein, the protein whose aggregates eventually destroy midbrain dopaminergic neurons in PD (and that are the cause of other diseases collectively known as the synucleinopathies), first aggregates “in enteric neurons, the neurons that control gastrointestinal function,” Collin Challis told BioWorld.